Activity Summary:

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.

Activity Summary:

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.

Activity Summary:
This activity will inform participants about the complex pathophysiology of NF1-PN and how an understanding of molecular pathways has led to the development of MEK inhibitors. The key published and ongoing clinical evidence on the utility of approved and emerging therapies for NF1-PN will be detailed to provide a strong foundation for clinical decision-making. An in-depth guide to recognize and diagnose patients with NF1-PN will also be discussed in this module to facilitate an accurate and timely diagnosis. Overall, this presentation will ensure that participants appreciate the need to recognize and treat NF1-PN among pediatric patients.

Activity Summary:
This activity will inform participants about the complex pathophysiology of NF1-PN and how an understanding of molecular pathways has led to the development of MEK inhibitors. The key published and ongoing clinical evidence on the utility of approved and emerging therapies for NF1-PN will be detailed to provide a strong foundation for clinical decision-making. An in-depth guide to recognize and diagnose patients with NF1-PN will also be discussed in this module to facilitate an accurate and timely diagnosis. Overall, this presentation will ensure that participants appreciate the need to recognize and treat NF1-PN among pediatric patients.

Activity Summary:
Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke risk.

Activity Summary:
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this Clinical Clip activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Activity Summary:
Stroke prevention continues to challenge clinicians, especially when balancing effective anticoagulation with the risks of bleeding. During this video series, Dr.'s C. Michael Gibson and Manesh Patel provide rapid updates on the latest science shaping stroke prevention. Each 10–15-minute episode delivers digestible insights on topics such as emerging anticoagulation strategies, residual stroke risk, and clinical trial takeaways. This series is perfect for time-pressed healthcare professionals as it offers actionable knowledge designed to support evidence-based decision-making.

Activity Summary:
Myasthenia Gravis (MG) has had significant advances, however critical gaps persist in optimizing care. Challenges include variability in diagnostic accuracy, particularly in seronegative cases, and a limited adoption of newer, more sensitive testing modalities. Additionally, the evolving treatment landscape—with emerging therapies such as complement inhibitors and FcRn antagonists—highlights the need for clinicians to stay informed about the latest evidence and integrate these options into personalized care strategies. Addressing these gaps is crucial to improving patient care, enhancing quality of life, and reducing the burden of long-term side effects associated with traditional treatments.

This special edition podcast series with Dr. Nicholas Silvestri enables healthcare providers to engage with evidence-based insights and practical guidance on MG management at their convenience. The podcast format is ideal for professionals to access while commuting, during breaks, or between patient appointments, providing targeted learning without disrupting their workflow.

Activity Summary:
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this podcast activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Activity Summary:
In this podcast titled "Emerging Evidence in Myasthenia Gravis: Key Updates from AAN 2025," Dr. Nicholas Silvestri provides healthcare professionals with an actionable update on recent advancements in MG; which features insights from groundbreaking research presented at AAN 2025.

Activity Summary:
In this Clinical Clip, Dr. Nicholas Silvestri provides a concise and clinically relevant summary of the most important emerging data presented at AAN 2025 that impact the management of generalized Myasthenia Gravis (gMG).

Topics covered include pivotal updates from recent clinical trials—such as MINT (inebilizumab), ADAPT NXT (efgartigimod), and MycarinG (rozanolixizumab)—highlighting the safety, efficacy, and practical implications of emerging therapies across diverse MG subtypes. The activity also explores trends in real-world treatment patterns, therapeutic inertia among neurologists, and new diagnostic approaches including advanced serologic testing and AI-supported electrophysiologic tools. With a focus on individualized care, this activity equips healthcare professionals with key insights to help integrate new therapies and diagnostic innovations into practice, ultimately supporting timely, targeted, and patient-centered management of MG.

Activity Summary:
Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. 

In this video presentation, Dr Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:

Drs. Smith and Pellock will provide an expert analysis of the identification of Lennox-Gastaut syndrome in adults, optimal treatment options, and transition of care. The transition of pediatric patients to adults remains a challenge for providers and requires a global multidisciplinary approach.

Activity Summary:
Dr. Smith and Dr. DeToledo provide an expert review of refractory epilepsy, including proper diagnosis, imaging, seizure types, and treatment options including AEDs, surgery, VNS, and dietary considerations.